Apogee Therapeutics (APGE) Free Cash Flow (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Free Cash Flow data on file, last reported at -$55.4 million in Q1 2026.

• On a quarterly basis, Free Cash Flow changed 0.23% year-over-year to -$55.4 million in Q1 2026; TTM through Mar 2026 was -$232.8 million, a 18.97% decrease from a year earlier, with the FY2025 full-year figure at -$232.6 million, down 35.0% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$55.4 million, up from -$59.3 million in the prior quarter.
• Over the last five years, Free Cash Flow for APGE reached as high as -$9.2 million in Q4 2022 and fell as low as -$67.7 million in Q4 2024.
• Historically, Free Cash Flow has averaged -$38.9 million across 5 years, with a median of -$37.6 million in 2024.
• Across the five-year window, Free Cash Flow sank 223.8% in 2023 and grew 12.36% in 2025, its largest moves.
• Year by year, Free Cash Flow stood at -$9.2 million in 2022, then sank by 223.8% to -$29.8 million in 2023, then tumbled by 127.58% to -$67.7 million in 2024, then rose by 12.36% to -$59.3 million in 2025, then rose by 6.57% to -$55.4 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$55.4 million in Q1 2026, -$59.3 million in Q4 2025, and -$57.7 million in Q3 2025.